Benmelstobart (TQB2450) alone or combined with anlotinib in previously treated advanced endometrial cancer: updated results from a multicohort, open-label, multicenter phase II clinical trial TQB2450-II-08
第一作者机构:[1]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
推荐引用方式(GB/T 7714):
Wu Xiaohua,Chen Xiaojun,Luo Xuezhen,et al.Benmelstobart (TQB2450) alone or combined with anlotinib in previously treated advanced endometrial cancer: updated results from a multicohort, open-label, multicenter phase II clinical trial TQB2450-II-08[J].INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER.2024,34(SUPPL_3):A6-A6.doi:10.1136/ijgc-2024-IGCS.6.
APA:
Wu, Xiaohua,Chen, Xiaojun,Luo, Xuezhen,Wang, Ke,Wang, Dong...&Liao, Qinping.(2024).Benmelstobart (TQB2450) alone or combined with anlotinib in previously treated advanced endometrial cancer: updated results from a multicohort, open-label, multicenter phase II clinical trial TQB2450-II-08.INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER,34,(SUPPL_3)
MLA:
Wu, Xiaohua,et al."Benmelstobart (TQB2450) alone or combined with anlotinib in previously treated advanced endometrial cancer: updated results from a multicohort, open-label, multicenter phase II clinical trial TQB2450-II-08".INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 34..SUPPL_3(2024):A6-A6